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Abstract 
Background: Although recent studies indicate that epicardial adipose tissue expresses brown fat‑like genes, such 
as PGC1α, UCP1 and PRDM16, the association of these genes with type 2 diabetes mellitus (DM2) in coronary artery 
disease (CAD) remains unknown.
Methods: PGC1α, UCP1, and PRDM16 mRNAs expression levels were measured by real‑time PCR in epicardial and 
thoracic subcutaneous adipose tissue from 44 CAD patients (22 with DM2 [CAD‑DM2] and 22 without DM2 [CAD‑
NDM2]) and 23 non‑CAD patients (NCAD).
Results: The CAD‑DM2 patients had significantly lower PGC1α and UCP1 expression in epicardial adipose tissue than 
the CAD‑NDM2 and NCAD patients. However, PGC1α and UCP1 mRNA trended upward in subcutaneous adipose 
tissue from CAD‑DM2 patients. At multiple regression analysis, age, body mass index, left ventricular ejection fraction, 
UCP1 expression of epicardial adipose tissue and diabetes came out to be independent predictors of PGC1α levels. 
Epicardial adipose tissue PGC1α expression was dependent on the number of injured coronary arteries and logistic 
regression analysis showed that PGC1α expression in epicardial adipose tissue could exert a protective effect against 
coronary lesions.
Conclusions: DM2 is associated with decreased expression of PGC1α and UCP1 mRNA in epicardial adipose tissue of 
patients with CAD, likely reflecting a loss of brown‑like fat features. Decreased expression of PGC1α in human epicar‑
dial adipose tissue is associated with higher prevalence of coronary lesions.
Keywords: Epicardial adipose tissue, Peroxisome proliferator‑activated receptor gamma coactivator 1‑alpha (PGC1α), 
Coronary artery disease, Type 2 diabetes mellitus
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Background
In contrast to subcutaneous adipose tissue (SAT), epicar-
dial adipose tissue (EAT) represents a visceral fat depot 
that has not been fully characterized and that has gained 
significant attention in recent years. EAT is located 
between the myocardium and the inner layer of visceral 
pericardium [1]. Thus, due to the close anatomical prox-
imity to the heart and the absence of fascial boundaries, 
EAT has been implicated in the development of coronary 
disease artery (CAD).
Several studies have shown that EAT is associated 
with the development and progression of coronary ath-
erosclerosis, mainly through a dysbalance of pro/anti-
inflammatory adipokines production in pathological 
conditions [2–4]. Indeed, it has been demonstrated that 
the volume of EAT correlates with the extent and severity 
of CAD [4–6]. EAT participates in the energy homeosta-
sis of the heart and the vessels [7, 8]; thus the functional 
EAT might play a protector role over the myocardium or 
coronary arteries [9]. However, in patients with type 2 
diabetes mellitus (DM2), the EAT dysfunction might be 
the main connection between the diabetic state and com-
plexity of coronary lesions in patients with CAD. DM2 is 
associated with more extensive CAD, a more aggressive 
course and greater morbidity and mortality than in coro-
nary patients without DM2 [10].
Brown adipose tissue is a specialized tissue the function 
of which is to produce heat. Adipose mitochondria play 
an important role in fatty acid oxidation and adaptive 
thermogenesis, key adipose-specific metabolic pathways 
that are regulated by peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (PGC1α) [11, 12]. 
These pathways oxidize lipids and dissipate energy in the 
form of heat due to the uncoupling of the mitochondrial 
electron transport chain from the generation of ATP by 
uncoupling protein 1 (UCP1). On the basis of hundreds 
of studies, PGC1α is now recognized as a master regu-
lator of mitochondrial biogenesis and oxidative metabo-
lism in many cell types.
Recent studies have reported that human EAT 
expresses genes of the brown-like adipocytes, such as 
PGC1α, (UCP1), and PR-domain-missing 16 (PRDM16), 
suggesting that EAT may play a role in thermogenesis 
[13, 14]. However, it remains to be determined whether 
the brown fat-like gene expression in EAT is altered in 
CAD patients according to diabetes status. Therefore, our 
main objective was to evaluate the expression of PGC1α, 
UCP1 and PRDM16 mRNAs in EAT contiguous with 
CAD in patients with and without DM2. We hypoth-
esized that the gene expression of thermogenic genes in 
EAT would be altered according to diabetes status, since 
adipose thermogenesis has been shown to affect excess 
lipids and fat accumulation [15, 16]. An additional aim 
was to determine the possible association between brown 
fat-like gene expression and various biochemical and 
clinical parameters that it could explain the prevalence of 
coronary lesions in diabetic patients.
Methods
Patients
A total of 44 patients who underwent coronary artery 
bypass grafting CABG (CAD group, 38 men and six 
women) and 23 patients who underwent aortic and/
or mitral valve replacement (patients without CAD 
(NCAD), 12 men and 11 women) were enrolled in this 
study. The CAD group was divided into two groups: 
those with DM2 (CAD-DM2, 18 men and four women) 
and those without DM2 (CAD-NDM2, 20 men and two 
women). The CAD group was defined by the presence 
of at least one coronary stenosis ≥50 % of luminal diam-
eter by coronary angiogram. The NCAD group (12 men 
and 11 women) had chronic valvular heart disease with 
or without stenosis less than 50  % in any vessel requir-
ing valve replacement but not CABG and without DM2. 
Exclusion criteria were acute inflammatory disease, 
severe infective disease and/or cancer, and women who 
were taking hormone replacement therapy. DM2 was 
defined as having a history of diabetes diagnosed and/or 
treated with medication, fasting blood glucose ≥126 mg/
dl and/or glycated hemoglobin (HbA1c)  ≥6.5. All 
patients gave written informed consent, and the study 
was reviewed and approved by the Ethics and Research 
Committee of Virgen de la Victoria Clinical University 
Hospital, Malaga, Spain, and carried out in accordance 
with the Declaration of Helsinki.
Biological material
Human EAT biopsy samples (average 0.2–0.5  g) were 
taken near the proximal right coronary artery and SAT 
(average 1.5–2 g) was obtained from the thorax. Thoracic 
SAT biopsies were taken 30–45 min after anesthesia and 
EAT biopsies were taken approximately 1  h after anes-
thesia. All the tissues were frozen immediately in liquid 
nitrogen and stored at −80 °C for RNA isolation.
Blood assays
On the morning of surgery, peripheral venous blood was 
drawn into pyrogen-free tubes with or without EDTA as 
an anticoagulant. For serum, the tubes were left at room 
temperature for 20 min and then centrifuged at 1500g for 
10 min at 4 °C. Fasting glucose, HbA1c, total cholesterol, 
low-density lipoprotein (LDL), high-density lipoprotein 
(HDL), triglycerides and creatinine were measured in a 
Dimension autoanalyzer (Dade Behring Inc., Deerfield, 
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IL) by enzymatic methods (Randox Laboratories, Ldt., 
UK) in the hospital laboratory.
RNA isolation and TaqMan real‑time reverse transcription–
polymerase chain reaction
Adipose tissue samples were minced in TriZol reagent 
(Invitrogen) and homogenized completely on ice. Total 
RNA was extracted by chloroform and purified through 
RNeasy minicolumns. After on-column DNase treat-
ment, RNA was eluted with Rnase-free water. Total 
RNA was quantified with a spectrophotometer (Nan-
odrop N-100, Thermo Scientific), and all samples had a 
260/280  nm absorbance ratio  ≥1.8. Reverse transcrip-
tions were performed using 1 μg of total RNA with Tran-
scriptor First Strand cDNA Synthesis Kit (Roche) and 
random hexamers in 20  μl reaction. The gene expres-
sion levels in the adipose tissue were determined by 
real time quantitative polymerase chain reaction (PCR) 
using a predesigned and validated Taqman primer/probe 
sets [UCP1 (Hs00222453_m1, RefSeq NM_021833.4), 
PGC1α (Hs01016719_m1, RefSeq NM_013261.3), 
PRDM16 (Hs00922674_m1, RefSeq NM_022114.3) and 
cyclophilin A (Hs99999904_m1, RefSeq NM_021130.3)]. 
Real-time PCR amplifications were performed on 
96-well plates in reaction buffer containing Taqman Uni-
versal PCR Master Mix (No AmpErase UNG, Applied 
Biosystems, USA), 150  nM Taqman probe, 900  nM 
primers, and 22.5  ng cDNA. PCR reaction conditions 
were 48 °C for 30 min, 95 °C for 10 min, followed by 40 
cycles of 95 °C for 15 s and 60 °C for 1 min using an ABI 
7500 Fast Detection System (Applied Biosystems). Data 
were obtained as Ct values according to the manufactur-
er’s guidelines (the cycle number at which logarithmic 
PCR plots cross a calculated threshold line) and were 
used to determine ΔCt values (ΔCt  =  Ct of the target 
gene minus Ct of the housekeeping gene). Cyclophilin A 
transcripts were amplified in the same reaction to nor-
malize for variance in input RNA. mRNA expression 
levels relative to cyclophilin A were calculated by the 
2−ΔCt method. All tests were performed in duplicate. A 
negative control, RNA amplification without previous 
retrotranscription, was done to test for possible genomic 
DNA contamination.
Statistical analysis
Normality of continuous variables was checked by means 
of the Kolmogorov–Smirnov test. Continuous vari-
ables are expressed as mean  ±  standard deviation, and 
as the mean ± SEM in figures and compared by the use 
of analysis of variance and the post hoc analysis Bonfer-
roni test or with the Student’s test. Differences between 
EAT and SAT were analyzed with the paired Student’s t 
test. Categorical variables expressed as proportion and 
compared by use of Chi squared test. The Pearson cor-
relation coefficient was calculated to estimate the linear 
correlations between variables. Independent predictors 
of EAT PGC1α mRNA levels were determined by mul-
tiple regression analysis and variables achieving P < 0.05 
on correlation analysis were included. To define the risk 
factors of the development of coronary lesions, multi-
ple logistic regression analysis was used and odds ratios 
(OR) were calculated. The inclusion of 3 patients in each 
group, for a a-value of 0.05, (assuming a difference of 1.28 
and a standard deviation of 0.28), has the power to detect 
a significance difference of 95 %. Statistical analyses were 
performed with SPSS for Windows version 15 (SPSS Inc. 
Chicago, IL, USA). Values were considered to be statisti-
cally significant when P < 0.05.
Results
General characteristics of the patients
The general characteristics of the patients in the three 
groups are summarized in Table  1. No differences 
between the group of CAD patients with and without 
DM2 were found for either established risk factors, con-
sumption of medications or general clinical characteris-
tics. Diabetic treatment of CAD patients with DM2 was: 
only diet (n = 4, 19 %), oral anti-diabetic (n = 12, 57.1 %), 
oral anti-diabetic and insulin (n  =  4, 19  %) and only 
insulin (n = 1, 4.9 %). No patient was taking thiazolidin-
ediones. Percentage of CAD-DM2 patients on oral-anti-
diabetic were: metformin, 73 %, sulfonylureas (gliclazide 
and glibenclamide), 23 %.
Thermogenic gene mRNA expression in EAT and SAT
To investigate possible differential expression between 
the two groups of CAD patients (DM2 and NDM2) 
and NCAD, mRNA expression levels of EAT and SAT 
brown fat genes were evaluated. Values are gives as fold 
increase relative to the NCAD group and differences 
between groups were considered significant at P < 0.05 
(Fig. 1).
PGC1α and UCP1 mRNAs in EAT were significantly 
lower in the CAD-DM2 patients compared with the 
CAD-NDM2 patients (P = 0.027 and P = 0.038, respec-
tively) and NCAD patients (p  =  0.031 and p  =  0.045, 
respectively) (Fig.  1a, b). However, in contrast to EAT, 
there was a trend for higher PGC1α and UCP1 mRNA 
expression levels in the SAT from the CAD-DM2 patients 
compared with the CAD-NDM2 patients, though it was 
not statistically significant (Fig.  1d, e). PRDM16 mRNA 
expression was lower in the EAT (Fig. 1c) and higher in 
the SAT (Fig.  1f ) from the CAD group compared with 
NCAD, but it was not statistically significant.
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Comparison of the mRNA level of thermogenic genes 
from epicardial versus thoracic subcutaneous fat tissue 
in patients with CAD
To elucidate potential pathophysiological implications in 
gene expression, we compared the expression profile of the 
target genes involved in thermogenic and mitochondrial 
function in the EAT and SAT of patients with CAD (Fig. 2).
PGC1α mRNA levels were significantly higher (1.6-
fold) in thoracic SAT that in EAT (P  =  0.0029). Con-
versely, UCP1 mRNA levels were significantly lower 
(13-fold) in thoracic SAT than in EAT (P  <  0.0001). 
PRDM16 mRNA was similar in EAT and SAT.
Association between PGC1α mRNA expression in epicardial 
and thoracic subcutaneous adipose tissue and clinical 
variables
The PGC1α mRNA expression levels in EAT correlated 
positively with HDL cholesterol (r  =  0.498, P  =  0.004), 
LVEF (r  =  0.376, P  =  0.014), and EAT UCP1 mRNA 
expression (r = 0.307, P = 0.043) and negatively with the 
BMI (r  =  −0.431, P  =  0.025), serum levels of triglycer-
ides (r = −0.468, P = 0.005). Indeed, EAT PGC1α mRNA 
expression levels differed with the number of injured 
coronary arteries (P  =  0.0005) (Fig.  3). Thus, PGC1α 
mRNA expression was higher in patients with one or 
two injured coronary arteries (2−ΔCt =  0.0038 ±  0.0014) 
than in those with three or left main trunk injured coro-
nary arteries (2−ΔCt  =  0.0023  ±  0.0013). Considering 
only men, EAT PGC1α mRNA expression levels with the 
number of injured vessels remained statistically signifi-
cant (P = 0.020). Multiple regression analysis showed that 
BMI (β = −0.081, P =  0.048; 95  % CI −0.162, −0.001), 
LVEF (β  =  0.043, P  =  0.006, 95  % CI 0.013, 0.072), age 
(β = 0.072, P = 0.003, 95 % CI 0.026, 0.117), EAT UCP1 
mRNA levels (β = 0.148, P = 0.001, 95 % CI 0.063, 0.233) 
and DM2 (β = −0.929, P = 0.044, 95 % CI −1.832, −0.026) 
were independently associated with EAT PGC1α mRNA 
levels (Table 2). Finally, logistic regression analysis showed 
Table 1 Clinical and laboratory characteristics of coronary patients according to the presence of type 2 diabetes mellitus, 
and non-CAD patients
Comparison between the results of the different groups was made with the Student’s t test or with the analysis of variance (ANOVA) and Chi square test for continuous 
and categorical data, respectively. Values were considered to be statistically significant when P < 0.05
CAD coronary artery disease; n no. of subjects; BMI body mass index; LVEF left ventricle ejection fraction; CVA cerebrovascular accident; ACEI angiotensin converting 
enzyme inhibitor; ARB angiotensin II receptor blocker; LDL low‑density lipoprotein; HDL high‑density lipoprotein; HbA1c glycated hemoglobin
p value: overall comparison for all groups
p value*: NCAD vs CAD‑NDM2 comparison
p value**: NCAD‑ vs CAD‑DM2 comparison
p value***: CAD‑NDM2 vs CAD‑DM2 comparison
NCAD CAD‑NDM2 P value* CAD‑DM2 P value** P value*** P value
Gender, n (M/F) 12/11 20/2 0.007 18/4 0.057 0.664 0.01
Age (years) 62 ± 11 63 ± 11 0.762 65 ± 9 0.323 0.513 0.619
BMI (kg/m2) 27.8 ± 5.3 28.2 ± 6.4 0.820 29.8 ± 5.7 0.229 0.386 0.481
LVEF (%) 57.7 ± 12.4 51.7 ± 8.0 0.05 51.2 ± 4.2 0.024 0.796 0.031
Risk factors, n (%)
 Dyslipidemia 10 (43.5) 15 (68.2) 0.136 18 (81.8) 0.013 0.487 0.021
 Hypertension 21 (91.3) 17 (77.2) 0.242 20 (90.9) 0.99 0.412 0.296
 Current smoking 7 (30.4) 14 (63.6) 0.04 7 (31.8) 0.99 0.07 0.04
 CVA 2 (8.7) 1 (4.5) 0.578 2 (9.1) 0.962 0.549 0.812
Medications, n (%)
 Aspirin 13 (56.5) 8 (36.4) 0.236 14 (63.6) 0.763 0.131 0.170
 Statin 9 (39.1) 8 (36.4) 0.85 12 (54.5) 0.376 0.364 0.421
 ACEI/ARB 6 (26.1) 5 (22.7) 0.796 10 (45.4) 0.221 0.202 0.213
 Beta‑blocker 15 (65.2) 8 (36.4) 0.076 14 (63.6) 0.912 0.131 0.094
Biochemical data
 Glucose (mg/dL) 106.00 ± 18.93 103.00 ± 20.10 0.61 153.86 ± 41.51 <0.0001 <0.0001 <0.0001
 Cholesterol (mg/dL) 161.88 ± 41.98 165.47 ± 30.17 0.74 143.88 ± 34.29 0.12 0.032 0.109
 LDL‑cholesterol (mg/dL) 97.24 ± 31.76 102.95 ± 27.1 0.52 81.68 ± 23.29 0.068 0.008 0.04
 HDL‑cholesterol (mg/dL) 40.70 ± 14.32 36.47 ± 11.43 0.28 29.75 ± 6.44 0.002 0.020 0.008
 Triglycerides (mg/dL) 119.76 ± 44.59 153.23 ± 61.3 0.041 187.58 ± 55.12 <0.0001 0.057 0.0005
 HbA1c 5.46 ± 0.63 5.91 ± 0.61 0.02 7.51 ± 0.90 <0.0001 <0.0001 <0.0001
 Creatinine (mg/dL) 1.00 ± 0.32 1.24 ± 0.80 0.16 1.20 ± 0.51 0.11 0.79 0.329
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the PGC1α mRNA expression in EAT to be a protective 
factor against the number of injured coronary arteries 
(OR = 0.310; P = 0.037, 95 % CI = 0.103, 0.931). However, 
circulating triglyceride levels were associated with a higher 
risk of suffering coronary lesions (OR = 1.023; P = 0.044, 
95 % CI = 1.001, 1.046; p < 0.05) (Table 3).
Discussion
Although there is existing research linking brown fat-like 
gene expression in EAT to the metabolic syndrome and 
DM2 [13], this is the first study to focus on EAT and SAT 
brown fat-like gene expression from CAD patients with 
DM2 itself.
Our main finding was that CAD patients with DM2 
expressed significantly lower PGC1α and UCP1 mRNA 
levels in EAT than those without DM2 and NCAD 
patients. Conversely, the mRNA expression of these brown 
fat-like genes trended upward in SAT from CAD patients 
with DM2 and NCAD patients. We found that EAT 
PGC1α mRNA levels correlated positively with HDL-cho-
lesterol, LVEF, and EAT UCP1 mRNA levels and negatively 
with BMI, circulating triglycerides. Multiple regression 
analysis showed that age, BMI, LVEF, EAT UCP1 expres-
sion and diabetes were independent predictors of PGC1α 
mRNA levels in EAT. We also found that PGC1α expres-
sion levels in EAT decreased with the number of injured 
coronary arteries and EAT PGC1α was shown as a possi-
ble protective factor against coronary lesions.
In line with previous research [14, 17], we found that 
UCP1, the specific marker of brown adipocytes, is 
Fig. 1 PGC1α, UCP1 and PRDM16 mRNA expression levels in EAT and SAT. TaqMan® real time PCR for PGC1α, UCP1 and PRDM16 was performed on 
human EAT (a–c) and thoracic SAT (d–f) from coronary artery disease (CAD) patients with type 2 diabetes (CAD‑DM2) (n = 22) and without it (CAD‑
NDM2) (n = 22) and non‑CAD patients (NCAD) (n = 23). Results were expressed as the mean ± SEM of the completed experiment in duplicate. 
*P < 0.05 vs CAD‑NDM2 and #P < 0.05 vs NCAD. PGC1α peroxisome proliferator‑activated receptor gamma coactivator‑1 alpha; UCP1 uncoupling 
protein 1; PRDM16 PR domain containing 16; EAT epicardial adipose tissue; SAT subcutaneous adipose tissue
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expressed in human EAT, confirming the possibility that 
EAT functions like brown adipose tissue. It has been 
reported that beta adrenergic stimulation cannot induce 
UCP1 in brown adipose tissue that lacks PGC1α activity 
[16]. Interestingly, most factors that induce or repress the 
browning program act through modulation of PGC1α 
activity [12]. Therefore, the lower expression of EAT 
PGC1α and UCP1 from CAD patients found in our study 
suggests a loss of EAT brown-like features in DM2, which 
Fig. 2 Comparison of PGC1α, UCP1 and PRDM16 mRNAs in EAT and 
SAT. TaqMan® real‑time PCR analysis for mRNA expressions of PGC1α 
(a), UCP1 (b) and PRDM16 (c) in human adipose tissues (EAT and 
SAT) from coronary artery disease (CAD) patients. mRNA expression 
in thoracic SAT were compared as a fraction of epicardial fat, which 
was arbitrarily assigned the value of 1. Results were expressed as the 
mean ± SEM of the completed experiment in duplicate (n = 36). 
PGC1α peroxisome proliferator‑activated receptor gamma coactiva‑
tor‑1 alpha; UCP1 uncoupling protein 1; PRDM16 PR domain contain‑
ing 16; EAT epicardial adipose tissue; SAT subcutaneous adipose tissue
Fig. 3 Association between PGC1α mRNA expression in EAT and 
coronary lesions. Dot plots represent PGC1α mRNA levels detected 
by real‑time PCR in the group of patients regarding injured coronary 
arteries (1 or 2 and 3 or main trunk). Student’s t test was used to 
determine differences among the groups. P = 0.005. PGC1α peroxi‑
some proliferator‑activated receptor gamma coactivator‑1 alpha; EAT 
epicardial adipose tissue, N number of subjets
Table 2 Multiple regression analysis for prediction of EAT 
PGC1α mRNA levels
Values were considered to be statistically significant when P < 0.05
EAT epicardial adipose tissue; PGC1α peroxisome proliferator‑activated receptor 
gamma coactivator 1 alpha; CI confidence interval; BMI body mass index; DM2 
type 2 diabetes mellitus; LVEF left ventricle ejection fraction; UCP1 uncoupling 
protein 1
Variable EAT PGC1α mRNA (R = 0.789; R2 = 0.623)
β 95 % CI lower 95 % CI upper P value
Age 0.072 0.026 0.117 0.003
BMI −0.081 −0.162 −0.001 0.048
Gender −0.848 −1.841 0.146 0.092
DM2 −0.929 −1.832 −0.026 0.044
LVEF 0.043 0.013 0.072 0.006
Dyslipidemia 0.272 −0.578 1.122 0.518
Triglycerides 0.007 0.000 0.014 0.053
EAT UCP1 mRNA 0.148 0.063 0.233 0.001
Table 3 Logistic regression analysis for prevalence of cor-
onary lesions
Values were considered to be statistically significant when P < 0.05
OR odds ratio; CI confidence interval; PGC1α peroxisome proliferator‑activated 
receptor gamma coactivator 1 alpha; BMI body mass index
Variable OR (95 % CI) P value
PGC1α mRNA 0.310 (0.103–0.931) 0.037
Age 1.137 (0.954–1.355) 0.151
Gender (man) 27.908 (0.823–946.906) 0.064
BMI 0.948 (0.774–1.162) 0.608
Dyslipidemia 3.240 (0.332–31.602) 0.312
Triglycerides 1.023 (1.001–1.046) 0.044
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may act detrimentally on metabolism [18, 19] and pro-
mote the progression and severity of CAD [9].
To determine possible regional differences of fat tissue 
and brown fat-like gene expression, fat depots of epicar-
dial and thoracic adipose tissues were compared in each 
CAD patient. We found that EAT exhibited significantly 
higher expression of UCP1 and lower expression of 
PGC1α than thoracic SAT. Our data confirm and extend 
previous results demonstrating higher UCP1 mRNA 
expression in EAT than in SAT [13, 17]. However, the 
significantly reduced PGC1α mRNA expression in EAT 
found in our study is in contrast with the earlier studies, 
which found that PGC1α mRNA expression was higher in 
EAT [13, 17]. This might be due to a different number of 
diabetic patients in each study, as we showed that PGC1α 
mRNA expression was altered in each fat depot accord-
ing to the diabetes status, so it was lower in EAT from 
diabetic patients, but higher in SAT. Although PGC1α 
mRNA expression was higher in SAT, its contribution to 
CAD should be higher in EAT due to its close proximity 
to the coronary arteries [1]. Thus, we also found a nega-
tive association between PGC1α expression in EAT and 
injured coronary artery number, but SAT PGC1A expres-
sion was not associated with greater prevalence of CAD.
PGC1α is pivotal in lipid metabolism and mitochon-
drial function because it controls genes involved in fatty 
acid oxidation and the mitochondrial respiratory chain 
[16, 20]. A reduced expression of genes involved in fatty 
acid oxidation could be associated with altered lipid 
uptake in the adipose tissue [7, 21]. Then, a reduced 
clearance of circulating lipids by adipose tissue would 
also be expected. Accordingly, circulating triglyceride 
levels were higher in CAD patients with DM2. Moreo-
ver, EAT PGC1α mRNA levels correlated positively with 
HDL-cholesterol levels and negatively with circulating 
triglyceride levels. Our data support the involvement of 
EAT in lipid metabolism proposed by Chechi et al. [17] 
and the possible contribution of brown adipose tissue 
to triglyceride clearance and metabolism [18, 22]. The 
positive correlation found in our study between PGC1α 
and UCP1 mRNAs in EAT may reflect the regulation of 
UCP1 expression by PGC1α [11].
The lower PGC1α mRNA expression in EAT from CAD 
patients with DM2 might contribute to the lower clear-
ance of circulating triglycerides, possibly due to reduced 
PGC1α and UCP1-mediated β-oxidation of fatty acids 
in EAT, which may be accompanied by a suppression of 
adipocyte fatty acid uptake [21, 22]. PGC1α-mediated 
reduced β-oxidation of fatty acids and EAT-mediated 
reduced triglyceride clearance might expose the heart 
to excessively high circulating levels of lipids, leading to 
lipid-induced cardiotoxicity and, with EAT-mediated 
lower HDL-cholesterol, which has anti-inflammatory and 
anti-atherosclerotic properties, increase the risk and the 
severity of CAD. Moreover, due to EAT and myocardium 
sharing the same blood supply, a PGC1α and UCP1-
mediated reduced β-oxidation of fatty acids in EAT might 
also alter the functionality of the myocardium such that it 
does not provide sufficient energy. Thus, we also found 
that EAT PGC1α mRNA expression correlated positively 
with LVEF, it was inversely associated with the number of 
injured coronary arteries and was shown as a protective 
factor against CAD progression. Together, these findings 
are also consistent with studies implicating a relationship 
between adipose mitochondria dysfunction and meta-
bolic and cardiac complications [15, 20, 23].
Numerous studies have investigated the association 
between PGC1α gene expression in skeletal muscle and 
DM2, with conflicting results [24]. However, the associa-
tion of PGC1α mRNA in adipose tissue with and with-
out DM2 and CAD has been less studied, ours being the 
first study in the epicardial depot. A central question is 
whether reduced PGC1α and UCP1 mRNA expression 
in EAT is a prelude to the development of DM2 through 
a constitutively lower rate of β-oxidation and lower adi-
pose activation, or a consequence of the diabetes itself, in 
either case leading to increased severity of CAD. Future 
studies should focus on elucidating mechanisms by 
which EAT is involved in development and progression 
of CAD in various disease populations.
Study limitations
All the subjects were patients with valvular heart dis-
ease or CAD. Only small samples of EAT were col-
lected from each patient and they were insufficient for 
a thorough analysis and correlation between mRNA and 
protein.
Conclusions
In conclusion, the results of the study showed that DM2 
is associated with decreased PGC1α and UCP1 mRNA 
expression in EAT of patients with CAD, likely reflecting a 
loss of brown-like fat features. Another important finding 
was that a decreased expression of PGC1α in human EAT 
is associated with higher prevalence of coronary lesions. 
In addition, PGC1α was shown as possible protective fac-
tor against coronary lesions. These low levels of PGC1α, a 
master regulator of oxidative metabolism and mitochon-
drial function, could have important repercussions on 
the pathways regulated by PGC1α in EAT. Thus, PGC1α 
might represent a possible pharmacological target in dia-
betes-related coronary disease.
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